UNSPSC 51461503: Aesculus

This classification denotes a natural product, derivations of which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U76MXL14N and which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 28714 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Rosanae, Order Sapindales, Family Sapindaceae, and Genus Aesculus L., more commonly known as AESCULUS.

Aesculus bears the USDA PLANTS Identifier AESCU. European Medicines Agency schedules aesculus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33806.

UNSPSC 51461503 Aesculus is a Commodity code for pharmaceutical products, specifically horse chestnut seed extract and related botanicals used in medicinal preparations. State and local governments procure under this code primarily through multistate cooperative purchasing vehicles that aggregate demand across health departments, correctional facilities, state hospitals, and participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body; cooperative purchasing structures allow individual states and local entities to access negotiated pharmaceutical pricing without issuing separate RFPs. Scope under this code encompasses pharmaceutical products meeting FDA requirements, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance, with vendors supplying through authorized wholesalers and maintaining detailed product data including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations. Vendors must demonstrate pricing flexibility through fixed pricing, net price formats, or WAC-minus structures, maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and hold contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co.).

MMCAP's January 2026 RFP for Generic Multi-Source Pharmaceuticals and OTC Products, due March 26, 2026, covers participating state and local government facilities in Minnesota and Oregon. Evaluation emphasizes price competitiveness at 75 percent of scoring, with remaining weight on fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors will supply through authorized wholesalers effective July 1, 2026, under a two-year initial contract term with optional extensions at MMCAP's discretion for new responders; incumbent responders' amendments extend through June 30, 2028. Questions close February 18, 2026, and all products must be available in the marketplace and possess expiration dates of at least one year from manufacture with a minimum six-month shelf life. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific dollar value or budget range is disclosed; MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, and member-specific needs.